Incretin-Related Drug Therapy in Heart Failure

摘要: The new pharmacological classes of GLP-1 agonists and DPP-4 inhibitors are now widely used in diabetes have been postulated as beneficial heart failure. These proposed benefits arise from the inter-related pathophysiologies failure (diabetes increases risk failure, can induce insulin resistance) also light dysfunctional myocardial energetics seen normal utilizes predominantly fatty acids for energy production, but there is some evidence to suggest that increased glucose uptake may be failing heart. Thus, agonists, which stimulate glucose-dependent release enhance uptake, become a focus investigation both animal models humans with Limited pilot data shows potential improvements systolic function, hemodynamics, quality life, forming basis current phase II trials.